Research activities - fpscience
- Research activities - fpscience
- 40th EORTC-PAMM Winter Meeting - infocongressi.com
- 37th EORTC-PAMM Winter Meeting - EORTC : EORTC
- 40th EORTC-PAMM Winter Meeting and Educational Course ...
- 40th EORTC-PAMM Winter Meeting - NVMO
[Entertainment] - PAMM namesake Pérez is giving away $50,000 a year. The 2019 prize goes to a U.S. painter
[Entertainment] - PAMM namesake Pérez is giving away $50,000 a year. The 2019 prize goes to a U.S. painter | Miami Herald
Experienta mea (un fel de CV)
submitted by verdany77 to robursa [link] [comments]
In February of 1967, a young man leapt to his death off of a London building. To this day, his identity remains unknown. Who was the Shell Centre John Doe?
John Doe's Death and Discovery: On the 25th of February 1967, in London, England, a man, believed to be aged roughly 31, committed suicide. He has never been identified. The following description, from the UK Missing Persons' Unit website, contains almost all the information which is known about his life and death: "jumped from the top of the Shell Building, Belvedere Road".
The "Shell Building" on Belvedere Road is officially known as the
Shell Centre (pictured here in 1963) though all records referring to John Doe use the former. It's an office building, owned by multinational oil company Royal Dutch Shell, better known simply as Shell. The building, which was finished in 1962, is located in the London Borough of Lambeth. Located in South London, Lambeth has an area of about 10 square miles, or 26 kilometers squared. In the 1960's, it had over 300,000 residents.
At the time, the Shell Centre had about 5000 employees. It consisted of one 27-storey central building, surrounded by three flanking 9-storey wings (known collectively as the "Upstream Building") as well as a separate building known as the "Downstream Building." In its early years, the building consisted of 12 escalators and 40 lifts. Today, all but the central building have been demolished. It's prominent on the South Bank of the Thames, and one of the tallest buildings in the UK.
Four years before, in 1963, the documentary series "Look at Life" had produced a segment on the Shell Centre. In the segment, narrator Tim Turner described the building as "Britain's largest office block" and "one of the most advanced offices in Europe".
If the young man could have had any connection to the building itself is unclear, but the Shell Centre is generally open to the public. At the time it received visitors from "all over the world", in the words of Tim Turner. A "vertical boomtown" according to the programme, it consisted not only of offices, but also "aids to comfortable living" such as shops on the ground floor, an office pool, a recreation area, a hair salon, and restaurants. Just across the road from the building is an exit from Waterloo Station - many employees would use it to commute.
Though I have no way of being sure, I believe the central building is the one from which the young man leapt. The building did have an observation deck at the time, which visitors could use to look at the city - sadly, it's possible that it's from here that he jumped.
Because they seem sure of the details, that the young man jumped of his own volition rather than an accidental fall or him being pushed, it seems that there were witnesses to the act itself. Not surprising, given the location. It's unclear what time of day the act occurred, but even after office hours, the building usually had a number of people inside and around, and below was a busy street.
In any case, the victim's body was retrieved by police fairly quickly after his death (hours at latest). But apparently, there was no way to identify the man. As such, he was given the placeholder name routinely used for male unidentified decedents: John Doe. To this day, that's officially the only name he has.
London, being such a big city, has had various John Doe cases over the years - in fact, out of the approximately 1500 unresolved cases of unidentified decedents in England, the largest share come from the London area. "London John Doe", as a result, isn't a title uniquely reserved for this decedent.
I have specifically called him Shell Centre John Doe as I wanted to use a name which was unique to him, but he's been referred to by various labels. The Unidentified Wikia uses the name "London John Doe (February 1967)". Shell Centre John's official case number, as given by the UK Missing Person's Unit website, is
07-027395.
But besides this, there's no one overall moniker for him. In fact, there's very little information on John Doe and his case at all. What little is available, I have put together here.
Description: Despite the fact that he would have still been recognizable when he was found, there is no publicly available visual of what Shell Centre John Doe looked like, or at least there is none which is currently accessible. There does not seem to have been a sketch or reconstruction released, nor have any post-mortem photographs been made public. Some physical description is given of the unidentified man, though not much.
John Doe was a smaller man, standing about 165 centimeters (or 5'4) and said to have a "thin" build. His believed race is listed as "Asian", which unfortunately isn't very specific. Note that in the UK, "Asian" is commonly (though not always) used to refer to South Asians specifically. In particular, there is a large population of individuals with heritage from the former British Raj and Ceylon - these territories constitute the modern countries of India, Pakistan, Myanmar, Sri Lanka, and the Maldives. However, there are also smaller populations of South Asian Britons with Afghani, Bhutanese, and Nepali heritage.
While South Asians are generally the group which is referred to when the term "British Asian" comes up, it's said this has begun to change in the last decade or so as the term has extended to include those of East and Southeast Asian heritage. However, the descriptor "Asian" by itself when used by UK police still tends to refer to South Asians specifically.
Here's some further explanation: the Unidentified section UK Missing Persons Unit's website, where John Doe is listed, groups the believed races of unidentified individuals using the same ethnic descriptions used in the Police National Computer database, which is utilized throughout the United Kingdom. According to these guidelines, unidentified decedents are classified into one of seven racial categories, referred to as the "IC 6+1 identity codes". Here are the different groups into which an individual can be classified, quoted from the UK Missing Person Unit's Missing Persons Data Report for 2014 and 2015:
- ‘IC1 White – North European’
- ‘IC2 White – South European’
- ‘IC3 ‘Black’
- ‘IC4 Asian’
- ‘IC5 ‘Chinese, Japanese or South East Asian’
- ‘IC6 ‘Middle Eastern’
- ‘IC0 Other
Here, the term "Asian" by itself is used to refer specifically to South Asians - there is a separate category for unidentified individuals believed to be of East or Southeast Asian descent. If one checks the "Asian" listing for unidentified individuals on the website, all refer to individuals believed to be South Asian. Thus, as John Doe falls into the IC4 classification, it appears he was (or at least was believed to be) of a South Asian ethnicity.
From a demographic standpoint, this is still a very broad group - most British South Asians trace their ancestry to India, Pakistan, or Bangladesh, though many fall into other South Asian groups. From a religious standpoint, they are also quite diverse - the largest plurality are Muslim, though there are also sizeable Hindu and Christian populations, and smaller populations belonging to other religions such as Sikhism and Buddhism (and of course, a fair percentage are atheists or agnostics).
The Borough of Lambeth has an Asian (all ethnicities, not just South Asian) population about 5% now: the majority of these are those of Indian or Chinese descent. I had some difficulty finding data on Lambeth's demographics around 1967 (the Census was taken in 1971, but I couldn't easily find it) so I'm not sure what the breakdown of the Asian population was at the time, but it was almost doubtlessly lower than it is today. While 5% isn't nothing, compared to other Boroughs of London, it is not very high. It's very possible that John Doe didn't live in Lambeth Borough, and that he lived in another part of the city (or, of course, that he didn't live in London at all). He could have easily travelled to the Shell Centre from a more distant location.
On a much more general level, it is true that in the 1950's and 1960's, there was a significant growth of the Asian population of Britain. First of all, there was a significant boom in migration to the UK from India, Pakistan, and Sri Lanka, and quite a few of these migrants ended up in the London area. In the post-war period of the 40's and 50's, in particular, many health care workers were recruited from the Indian subcontinent to help the UK's newly formed National Health Service.
Additionally, quite a few East Africans of Indian descent (mostly from Tanzania, Uganda, and Kenya) ended up in the UK during the mid- to late-1960's, many as a reaction to Africanization policies in those countries (though this wouldn't reach its peak until the 1970's). There was also some amount of migration from Indo-Caribbeans during this period. Finally, some Mauritians immigrated to the UK in the 1960's, though in lesser numbers than they later would come in the 1970's. The majority of the population of Mauritius is of Indian descent, with many members of this population retaining close ties to India. Most of the Mauritian immigrants to the UK in the 1960's were NHS recruits, similar to those from the subcontinent mentioned above. A significant number were nurses.
It's possible that John Doe might belong to any of the aforementioned ethnic groups (or, of course, that his background reflects another group not listed here). There's even a chance that the guess was incorrect, and that he was a different race altogether - the estimation, assuming it was made at the time of his death, was likely based simply off of his appearance and
maybe the work of a forensic anthropologist, rather than something more concrete like DNA (it's unclear if there's a DNA sample available for John Doe - more on that later). These kinds of guesses have been off before - they're usually correct, but it happens.
In the United States and Canada, at least, there's been a few cases over the years involving Doe's whose initial believed races and ethnicities turned out to be off. For example,
Bun Chee Nyhuis, a Thai-American woman murdered by her husband in 1983, was initially thought to be white, until a button from her clothing was traced to an Asian brand, leading to further examination of her hair and skull which confirmed she was actually Asian (her case was profiled on
this episode of Forensic Files). And
Melonie Biddersingh, a teenage girl who was murdered by her abusive father and stepmother in Toronto in 1994, was a Jamaican immigrant of mixed Black and South Asian heritage - though investigators varied on their guess regarding her race (from
"Indian" to "Nilotic" to "probably of North African descent"), they never got it completely correct until she was identified in 2012. While I would guess that the estimation of John Doe's race is probably accurate, without any indication that it's been proven through more concrete means, the possibility that he may have had a different background should not be eliminated.
Moving on, another possibility which is worth noting: it is possible that John Doe didn't live in the country at all - perhaps he was just visiting. It's believed that "a significant number" of the 1500 open cases involving unidentified decedents in the United Kingdom involve individuals of foreign nationality who died on UK soil.
And looking at his specific circumstances, this theory might fit. Travelling to commit suicide, sometimes referred to as "suicide tourism", is sadly very common - though in many cases the term refers to terminally ill patients who travel abroad to seek euthanasia, it can also refer to deaths which would fit the more traditional definition of suicide. In fact, Christopher Burgess of travel company Securely Travel even advises that "if a family member, friend or colleague ... organizes a trip, by themselves on the spur of the moment", it's worth checking on them.
Moving on from John Doe's ethnic background, there isn't much more physical description of him. It's said that John Doe's eye colour is unknown, though I don't know if it was really impossible for them to determine or if this is just due to the information not being recorded, and his hair colour is not listed. Finally, the unidentified man did have two "distinguishing marks" - one on his arm (not sure which one) and one on his left buttock. What kind of marks - scars, birthmarks, etc. - isn't stated.
There is one particularly interesting thing to note here: John Doe's suspected age range actually isn't a range at all. His age range, according to the UK Missing Person's Unit, is 31 to 31 years old. While an autopsy can determine general age range, knowing age down to the
year is not common for adult Doe's. I'm not sure if John Doe being 31 was simply a guess by investigators, or if there was an error when the information was entered, or if this just means that they somehow were able to determine his exact age.
It's worth noting that there's a few other cases of unidentified decedents on the UK Missing Person's Unit website where they have a specific age listed instead of a range - for example,
this unidentified man found deceased in Essex in 2000 is given a range of 65 to 65, and
this unidentified hypothermia victim found on a bench in Croydon in 2001 is described as 60 to 60 years of age. My guess is that all of these, including that of Shell Centre John Doe, are just cases where they chose to give a specific number age estimation rather than a range. Still, in regards to our John Doe, 31 is such an oddly specific number that it makes one wonder.
Possessions (and Possible Clues?): At the time of his death, John Doe was wearing a brown, flecked jacket and matching trousers. Underneath his jacket, he had on a white shirt and a maroon tie. He was wearing black socks and black shoes. A formal outfit, though not unusually so, especially not in 1967.
Besides the clothes he was wearing, John Doe was in possession of one more distinct article. He was wearing a yellow metal wristwatch, with a stainless steel back. It was made by the Swiss company Lusina. The serial number
712206 was printed on the back - more specific information about the model is not given, and unfortunately no photograph is provided.
I wasn't familiar with the watch company, so I did some research on them. Lusina, also known as
Lusina Watch Factory, was located in Geneva - they were founded by Ferdynand Pamm as
Pamm Watches in 1917, and over the years the company was known by a variety of names. By 1966, they'd started using the label
Pamm Frères, Montres Lusina (Pamm Brothers, Lusina Watches). The company went out of business around 1972 when Pamm and his wife passed away in a car accident, according to a family member. Many of their 1960's watches can be bought online - evidently, they were very active at that period.
John Doe's watch may give us a little more to work on in regards to his identity. Lusina was a "generic Swiss brand", not particularly significant or well-known today, and the cost of their watches varied a lot depending on the model. I have not been able to determine in which countries exactly they were sold, though through newspaper ads I have managed to find that among them were Canada and Australia, where they were apparently sold through the 1950's (a few examples have been sourced below).
What is interesting is that I could not find any evidence that Lusina watches were sold in the United Kingdom, at least under that name. Unlike in Canada and Australia, there do not appear to be any ads for Lusina in UK papers from the time. Off of
Newspapers.com, I could only find one instance of a Lusina wristwatch being sold in the UK in the 20th century - in a January 1976 listing from the Guardian, apparently secondhand, set to be auctioned among other items.
As a result, it's possible that the watch was acquired abroad, whether in John Doe's home country if he was in fact an immigrant or foreign national, or elsewhere.
Investigation: Unfortunately, there is very little information on the investigation regarding this case. I could find absolutely nothing indicating what kind of efforts might have been made to identify John Doe. It's unknown if his fingerprints or dentals were recorded.
I'm not sure what was done with his remains, either - if they were buried, if he was cremated, or what. As of 2019, there was still no standardized procedure for what police should do with the remains of unidentified decedents - the National Crime Agency "encourages" that they record dentals and fingerprints, take DNA samples, and bury the body in a marked single grave in case exhumation is necessary. And if there's no standardized procedure today, one can only imagine the state of it in 1967.
I attempted to search Find A Grave, but couldn't find any graves of an unidentified person who died in 1967 in Lambeth Borough or the surrounding areas. But then again, many cemeteries have not been fully archived on Find A Grave - in fact,
there are only 17 graves listed on the website from Lambeth Borough in 1967. As such, it's very possible he was buried in a marked or unmarked grave and it's not been put online (or that I somehow missed it).
Because it's unclear what was done with the remains, it's also unclear if it would be possible to exhume him for DNA sampling, or if that was already attempted or done at some point (obviously, DNA wouldn't have been considered in 1967).
Going on, there's not much more information on the case, even looking at contemporary sources. I looked on
Newspapers.com, as well as the archives of several London newspapers, but couldn't find a single article about a man jumping off the Shell Centre. Though I can't be sure, I have the impression that this case didn't receive a lot of attention from the public or press at the time. Why, I don't know - perhaps because John Doe was a suicide victim rather than homicide, this impacted how police went about involving the public.
I did manage to find one article which discusses John Doe, albeit briefly. But the article isn't contemporary - it's from only two years ago. "The heartbreaking stories of the unidentified bodies found in London over 40 years ago," it's titled.
"We've rounded up just some of the heartbreaking discoveries made by the police more than 40 years ago that remain unsolved," author Ellie McKinell explains. And then, the very third unidentified person listed: "The man who jumped from the Shell Building". Sure enough, it's our John Doe. But the article doesn't have much more information on his identity than what's listed on the website.
It's a great thing that John Doe's case is now listed online - this could allow someone who may have known him to find the listing, even today. Still, I do not see what reason there would be that there was (at least apparently - I will admit that maybe there was and the evidence of it just hasn't been digitized) no attempt made at the time to appeal to the public for information. I understand that there were technological limitations, but isn't it possible that reaching out through the papers could have helped identify him? Somebody must have known him and missed him.
Conclusion: In a few days, it will have been 54 years since Shell Centre John Doe took his own life. His is one of the oldest cases of an unidentified person listed on the UK Missing Persons Unit's website.
Who was John Doe? Could he have been a recent arrival to the country? If he was one of the recent South Asian migrants, such as one of the many NHS recruits, he may not have known very many people in the country. If he was an immigrant, I wouldn't be shocked if he had a family and loved ones in his home country who noticed his disappearance but due to technological and practical constraints of the time, were unable to investigate (or even just assumed he had fallen out of contact. It was harder for most people to keep in touch internationally in 1967).
Alternately, it's still very possible that he didn't live in England at all - maybe he was just visiting. I think the possibilities of John Doe being an immigrant or a visitor to the country (or even UK-born, though I think this would have made him more likely to have been identified) are all worth considering. But given how common it is for unidentified decedents to be foreign residents, I am leaning slightly more towards this possibility. If this is the case, similar reasoning could still apply in terms of why nobody has claimed him.
I also wonder if, if he was an immigrant, perhaps he entered without documents (assuming he wasn't an NHS worker, who would be more likely to have papers) ? Only because that would make it more likely there was no trace of him on paper. But then, I don't know what methods of investigation the police followed or how carefully they checked paper records. With such little information, it's hard to say much about the investigation at all.
And as such, all we can do is go back to what we do know. And what we do know is this: that on 25 February 1967, somebody decided to end his own life, and that nearly 54 years later, nobody even knows his name, let alone why he did it.
Discussion: Sadly, with such little information and no sign of progress in the case at this point, I'm not sure how high the chances are that John Doe will get his name back any time soon. At the same time, I don't want to be pessimistic - if his body is buried somewhere accessible, then DNA testing is a viable option. But with such a cold case and nothing to suggest it's being actively investigated currently, it would probably have to take a new lead.
If Shell Centre John was an immigrant or foreign national who left those who knew him behind, and that played into him not being identified, then I think there's a chance there are people out there still wondering what happened to him. For this reason in particular, it's a good thing that the case has been listed online, even if there's relatively little information on it. Besides that, I think it's generally important that John Doe isn't forgotten. He was somebody.
Of course, the first question: who was Shell Centre John Doe? Why wasn't he identified? Could he have been an immigrant? Or was he a foreign visitor to the country? What are other possible clues to his identity? And, so many years later, what are some measures which could be taken now to try and identify him?
My sources are listed below. Thank you for reading, and of course please share if you find any information I missed!
Sources: submitted by ramenalien to UnresolvedMysteries [link] [comments]
A thorough DD on $ALRN (Aileron Therapeutics)
What is Aileron Therapeutics & what do they do? * Aileron Therapeutics is a
clinical stage company developing a novel medicine, ALRN-6924, to improve the quality of life of cancer patients * Their long-term vision is to
protect cancer patients across a variety of chemotherapies for many different cancer indications. * Aileron is exploring collaboration opportunities regarding ALRN-6924 for chemoprotection, and in other areas where Aileron’s proprietary platform of stabilized cell-permeating peptides can be applied such as targeted protein degradation.
What is ALRN-6924? * Their Pipeline drug is intended for all cancer patients * ALRN-6924 is a
first-in-class dual MDM2/MDMX inhibitor * currently being evaluated in a Phase 1b/2 clinical trial to protect cancer patients against chemotherapy-induced toxicities * They believe that treatment of patients with ALRN-6924 can reduce the toxic effects of chemotherapy while having no adverse effect on the anti-cancer activity of chemotherapy against p53-mutant tumor cells.
How Does ALRN-6924 Work? * ALRN-6924 is a decoy that mimics p53 and selectively binds to MDMX + MDM2, activating p53 to induce cell cycle arrest * In cells with normal p53, ALRN-6924 activates p53 by blocking MDM2 and MDMX * Activated p53 initiates cell cycle arrest * Cells that are in cell cycle-arrest are less sensitive to chemotherapy * ALRN-6924 is only being developed for patients with p53-mutant cancers, which represent 50% of all cancer patients. * Links showing what I said in terms of how ALRN-6924 works & more information:
Link 1 Link 2 Link 3 Q1 Financials & Highlights * Cash, cash equivalents and investments as of March 31, 2020 were $12.7 million. * The Company has determined to focus its efforts on the development of ALRN-6924 as a chemoprotective agent, and does not plan to advance development of ALRN-6924 for any other program at this time * The Company believes that its cash, cash equivalents and investments as of March 31, 2020 will be sufficient to fund its operations and capital expenditure requirements into the first quarter of 2021. * Research and development expenses for the three months ended March 31, 2020 were $4.1 million, compared to $4.2 million for the three months ended March 31, 2019 * the Company expects that its quarterly expenditures on research and development will be lower for the remainder of 2020 as compared to the first quarter of 2020. * Net loss was $6.7 million for the three months ended March 31, 2020, compared to $7.2 million for the same period in 2019. * Based on the preliminary data from the Phase 1b trial, and historical rates of these toxicities in SCLC patients treated with topotecan, Aileron believes that ALRN-6924, when dosed before chemotherapy may have a chemoprotective effect on toxicities such as severe anemia and thrombocytopenia. * The Company plans to commence the schedule optimization part of the Phase 1b trial in June 2020. * The Company currently plans to report top-line final data for the dose optimization part of the trial and data for the schedule optimization part of the trial in the fourth quarter of 2020
Links to Q1 Financials/highlights: Link 1 Link 2 Recent events to positively impact Q2-Q4 * On October 29th, 2019
$ALRN Announced new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which ALRN-6924, a dual inhibitor of MDM2 and MDMX, prevented chemotherapy-related toxicities in cellular studies and mouse models of cancer * nonclinical results show that ALRN-6924 significantly reduces the toxic effects of chemotherapy in normal, healthy bone marrow cells and gastrointestinal tissues * On May 27th 2020,
$ALRN Announced the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer * Results emerging from the third dose level support the data observed with the previous two cohorts, where we observed a protective effect of ALRN-6924 for severe anemia and severe thrombocytopenia when compared to historical rates of those toxicities in SCLC patients treated with topotecan * On June 1st 2020,
$ALRN Announced positive interim data from the open-label Phase 1b dose optimization part of its ongoing Phase 1b/2 clinical trial. * A protective effect against severe chemotherapy-induced anemia and thrombocytopenia was observed across all dose levels as compared to historical controls * Across all three dose levels, no patients experienced febrile neutropenia or NCI CTC Grade 3/4 nausea, vomiting, diarrhea or fatigue, which are severe toxicities commonly observed with topotecan-treatment in this patient population * On June 4th 2020,
$ALRN Announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross proceeds of $10.0 million * In addition, Aileron has granted the underwriter a 30-day option to purchase up to 1,363,636 additional shares of common stock at the public offering price * The offering is expected to close on June 8, 2020
Corporate Presentation Highlights * ALRN-6924 Has Demonstrated Chemoprotection in Non-clinical Studies: * induced cell cycle arrest in human bone marrow cells in vitro * protected in dose- & schedule-dependent manner against topotecan-induced neutropenia and carboplatin/taxol-induced thrombocytopenia in vivo * Observed protection against gastrointestinal toxicity of chemotherapy in vivo *Link to the
Corporate Presentation Risks/negatives of the business * As found on their recent 10-Q & 10-K SEC Filings: * "We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be forced to delay, reduce and/or eliminate our research and drug development programs, reduce headcount, and future commercialization efforts, or take other actions that could adversely affect our business." * "d investments as of the date of this Quarterly Report on Form 10-Q will be sufficient to enable us to fund our current operations for at least 12 months from the date of issuance of the financial statements included in this Quarterly Report on Form 10-Q...We plan to seek to address this condition through the sale of common stock in public offerings and/or private placements, and through other capital sources, including collaborations with other companies or other strategic transactions." * "We are dependent on the success of our lead product candidate, ALRN-6924, which is currently in multiple clinical trials. Our clinical trials of ALRN-6924 may not be successful. If our trials prove unsuccessful or if we are unable to obtain approval for and commercialize ALRN-6924 or experience significant delays in doing so, our business will be materially harmed" * "We are pursuing the development of ALRN-6924 in combination with other approved therapeutics. If the FDA revokes approval of any such therapeutic, or if safety, efficacy, manufacturing or supply issues arise with any therapeutic that we use in combination with ALRN-6924 in the future, we may be unable to further develop and/or market ALRN-6924, or we may experience significant regulatory delays, and our business could be materially harmed." * "Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success." * "We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies" * "We may enter into strategic collaborations for the development, marketing and commercialization of ALRN-6924 and our other stabilized cell-permeating peptide product candidates. If those collaborations are not successful, the development, marketing and/or commercialization of our product candidates that are the subject of such collaborations would be harmed." * "If we fail to regain compliance with the requirements for continued listing on the Nasdaq Capital Market, our common stock could be delisted from trading, which would adversely affect the liquidity of our common stock and our ability to raise additional capital or enter into strategic transactions." * They have until September 2020 to reach compliance ** Links to the SEC Filings so you can more in-depth & read other info on the risks section:
10-Q &
10-K Important upcoming dates/events * Dose & schedule optimization will be announced Q2 of 2020 * Topline Data Results will be announced Q4 of 2020
Target price/forecasts *
CNN Money sets the target price at a median of $5 with a high of $8 *
TipRanks sets it as a strong buy with a target price of $5 *
NASDAQ website sets it as a strong buy with a target price of $5 *
Wall Street Journal sets the median target price at $5 with a high of $8
SEC Filings/documents I highly suggest you read! *
10-Q *
10-K *
Corporate Presentation *
First quarter highlights *
June 1st webcast Final thoughts/comments * Despite this company having it's risks, as all companies do, I personally feel good that this one will reach or at least come close to their target price * I feel that way due to the recent clinical trial result, they have been nothing but positive and the people taking part of the trials have not had any adverse effects so far. * If the Topline data is solid when it is announced in Q4, that will be very positive for the stock's price. * If ALRN continues to prove it's successful & gets FDA approval, this drug can easily be seen almost as a necessity for those with cancer as this drug's intention is to prevent the toxicity effects caused by chemotherapy, not only that, but the specific mutant cell they are Targeting is in 50% of all cancers. * That being said, ALRN-6924 has a huge market potential if it continues to be as successful as these clinical trials are proving to be. * Anyways, for me, I'll be purchasing a couple hundred shares and hold it through Q4 when the Topline Data is announced.
Remember everyone, what I write & say is my opinion and you should never take it as a fact. That's why I urge everyone and will always do so in every single post to please extend my DD by doing your own by reading everything I've attached and looking into the company themselves. I want to make sure you all are informed before making a decision and never act blindly.
I hope that I have been able to help out with this post & with all my other posts in anyway possible. Hopefully you've been able to learn how to improve your DD or at the very least, I hope I've been able to provide a great read lol
Anyways, I hope Everyone is having a good weekend! Take care :)
submitted by PradoMV96 to EducatedInvesting [link] [comments]
Oncotarget: Participating in the AACR 2021 Annual Meeting
https://youtu.be/jFCKcsSYKNQ The American Association for Cancer Research (AACR) organizes an annual meeting program covering some of the most recent discoveries in cancer research. The conference aims to highlight work from the best minds in research and medicine from institutions all over the world. Oncotarget, exhibited by its publisher Impact Journals, will be participating virtually at the AACR Annual Meeting this year.
Visit the Oncotarget website:
https://www.oncotarget.com/ Visit the Impact Journals website:
https://www.impactjournals.com/ As of June 2020, Scopus released their latest 2019 Journal Rankings on Oncology. Oncotarget is among their highest rated (Q1) journals and ranked number one in total citations in oncology. The journal has published outstanding papers and reviews by authors including Bert Vogelstein, Peter K. Vogt, Pier Paolo Pandolfi, Arnold J. Levine, Brian Druker, and Carol Prives. Founding Oncotarget Editorial Board members include Nobel Laureates Andrew V. Schally and Gregg L. Semenza; Lasker Award recipients Alexander Varshavsky, Brian J. Druker, and Gregg L. Semenza; and 16 members of the US National Academy of Sciences. Oncotarget is indexed and archived in PubMed, PubMed Central, Scopus, EMBASE, and META (Chan Zuckerberg Initiative). The 2021 AACR conference, a two-week online event, will take place from April 10-15 and May 17-21, 2021. Topics include population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy. In 2019, Oncotarget participated in the AACR Annual Meeting at the Georgia World Congress Center in Atlanta, Georgia, USA, and "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics," at the Hynes Convention Center in Boston, Massachusetts, USA. The total registration count from the 2019 AACR Annual Meeting was over 21,000—nearly 16,000 of which were scientific attendees from all over the world. Follow the Oncotarget Twitter account (@Oncotarget) for live updates about the conference using the #AACR21 hashtag.
About Oncotarget: Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit
https://www.oncotarget.com or connect with us:
SoundCloud -
https://soundcloud.com/oncotarget Facebook -
https://www.facebook.com/Oncotarget/ Twitter -
https://twitter.com/oncotarget Pinterest -
https://www.pinterest.com/oncotarget/ Reddit -
https://www.reddit.com/useOncotarget/ Oncotarget is published by Impact Journals, LLC please visit
https://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
[email protected] 18009220957
submitted by Oncotarget to Oncotarget [link] [comments]
$KURA - Kura Oncology DD
$KURA – Kura Oncology
Overview: Kura Oncology was created in 2007 and is based in California. The company is utilizing the genomic revolution to transform how cancer is treated, understanding that a patient’s response to treatment depends partially on the cancer’s genetic makeup. With an advancing pipeline of precision medicines for the treatment of both solid tumors and blood cancers, their small-molecule candidates specifically target signaling pathways and other drivers of cancers where there is a strong scientific and clinical rationale to improve the outcomes by identifying patients most likely to benefit from treatment.
The CEO of the company is well versed in the biotech industry as he is not only CEO of Kura, but also a member of the board of directors for Puma Biotechnology, Zosano Pharma, as well as president and CEO of Wellspring Biosciences, Araxes Pharma, and Avidity Biosciences. Along with his history in the biotech industry, his management, advisory, and leadership teams are all stacked with extensive experience. While the resume is quite impressive, it does strike concern in me that this man is a member of several executive boards as well as CEO and president of several different companies. I believe a pharma company that is pushing multiple candidates in their pipeline through Phase I and II studies should not have his attention diverted between 5+ different companies.
Anyways, the company has three primary focuses for their development. Precision Medicines, Targeted Therapeutics, and Biomarkers. Utilizing precision medicine, they want to discover and develop innovative therapies designed to inhibit abnormally functioning cellular pathways that drive cancer growth. These two categories will be paired with molecular diagnostics to identify biomarkers specific to tumors to better decide which patients will likely respond to treatments.
Pipeline: The company currently has 3 different candidates within its pipeline, with their flagship product being Tipifarnib. This oral, investigational drug candidate is currently being evaluated in multiple Phase II clinical trials for four different indications.
Tipifarnib – Farnesyl Transferase Inhibitor
KO-947 – ERK Inhibitor
KO-539 – Menin-MLL Inhibitor
Tipifarnib is the most advanced drug in their pipeline, the furthest developed at Phase II while the others are in Phase I and preclinical. We will discuss Tipifarnib below.
KO-947 is being evalued in Phase I, and operates by blocking the activity of the enzyme extracellular signal-regulated kinase (ERK), which is a critical component of signaling pathways that has been implicated in various cancer processes, including survival, growth, and proliferation of tumor cells. Phase I clinical trials are being conducted on patients with locally advanced unresectable or metastatic, relapsed, and/or refractory non-hematological malignancies. Below is a poster presentation of the studies and function of this drug candidate.
https://kuraoncology.com/wp-content/uploads/Burrows-AACR-2018.pdf KO-539 is being evaluated in preclinical testing for treatment of specific types of leukemia. Functioning by blocking the interaction of two proteins, menin and MLL that together, are critically important for survival, growth, and proliferation of certain kinds of leukemia cells. Below is a poster presentation of the research being conducted on this candidate.
https://kuraoncology.com/wp-content/uploads/2017-AACR-NCI-EORTC-Menin-Formatted-Poster-2017-10-18.pdf Specific Drug: While Kura has a relatively new pipeline, their main candidate is Tipifarnib. This flagship product is being studied for four different indications at the company, however we are focused on one specifically. For the indication of Head and Neck Squamous Cell Carcinomas (HNSCC), this mid October the company is going to be presenting updated data from their Phase II study at the European Society for Medical Oncology. In conjunction with that presentation, the company plans on initiating a pivotal trial in Phase III in the second half of 2018, which could very well land right around their presentation, providing a great opportunity for price action moving upwards.
Tipifarnib, an oral drug that functions by blocking the activity of an enzyme called farnesyl transferase. Protein farnesylation is a key signaling process implicated in various cancer processes, including survival, growth, and proliferation of tumor cells. With more than 5,000 oncology patients having been studied on the drug and observed to have manageable side effects, it is suggested that tipifarnib has the potential to provide benefits to specific cancer patients with limited treatment options.
For the specific indication and use in patients with Head and Neck Cancers, the company is evaluating tipifarnib in patients that carry HRAS mutations. HRAS is a proto-oncogene, a gene that has the potential to cause cancer, that when mutations occur or there is an increased expression, can cause this normal gene to become cancerous. Proto-oncogenes code for proteins that help regulate cell growth and differentiation, and HRAS is mutated or expressed in certain head or neck squamous cell carcinoma tumors. HRAS has been known for over 40 years, yet there are no targeted therapies for tumors with the mutated form of HRAS. The company hopes that its product tipifarnib will selectively inhibit farnesyltransferase, a critical enzyme for the activity in HRAS. The relapsed or refractory HNSCC patient population has a survival rate of six to eight months and existing therapeutic options only produce a response rate of 10 to 20 percent. For this reason, HRAS is often called an undruggable oncogene.
HRAS mutations are observed in 5% of HNSCC cases, generating a direct need that has no products to fill. Early research shows that tipifarnib induces deep, sustained regression in HRAS mutations. Clinical proof -of-concept has been achieved in HRAS mutated HNSCC cases with durable responses being observed. So farm, Kura’s research is demonstrating that HRAS is a targetable mutation in HNSCC and illustrates that there is potential for tipifarnib in the treatment of additional HRAS-mutant squamous cell carcinomas.
So far, preliminary Phase II data which will be updated soon demonstrates many positive points. Tipifarnib demonstrates an overall response rate of 83% in its patients and is not only generally well tolerated, but also shows a benefit in use. HRAS mutant HNSCC patients saw no benefit from prior therapies including chemotherapy, cetuximab, and immunotherapy, however patients had responded well or provided a partial response when treated with tipifarnib. This data is displaying that the mutant HRAS oncogenes are targetable as well as providing evidence that tipifarnib is effective for recurrent or metastatic HNSCC carrying HRAS mutations. This was confirmed in 5 of 6 HNSCC patients and did so with rapid responses where other treatments had failed to provide any response.
Here is a poster presenting the data, research, and more of the indication of tipifarnib in HNSCC.
https://kuraoncology.com/wp-content/uploads/Kessler-AACR-2018.pdf https://kuraoncology.com/wp-content/uploads/KO-TIP-001-HN-Scottsdale-Poster-44-in-by-40-in-v2018-02-12-FINAL.pdf Market Outlook and Competition: This market looks like it will continue to grow higher in the foreseeable future. Driven mainly by alcohol and tobacco abuse, it is expected that the global head and neck cancer market will grow at an astounding CAGR of 22.6% from 2018 to 2023. This would push the market to reach $2.3 billion by the end of that growth period. The World Health Organization estimates that there are more than 550,000 cases and nearly 300,000 deaths worldwide each year. Roughly 90% of head and neck cancers are squamous cell carcinomas, creating the sixth leading cancer by occurrence. An estimated 63,000 Americans developing head and neck cancer annually, and 13,000 dying of this disease. In Europe, there were approximately 250,000 cases of cancer registered and 63,500 deaths in 2012. Looking back at our numbers earlier, roughly 5% of these cases are due to HRAS mutations, the precise market that Kura is targeting and has no current, successful treatment option.
Drugs approved for head and neck cancer include Abitrexate (Methotrexate), Blenoxane (Bleomycin), Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Folex (Methotrexate), Folex PFS (Methotrexate), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Methotrexate LPF (Methotrexate), Mexate (Methotrexate), Mexate-AQ (Methotrexate), Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel). Drug combinations used in head and neck cancer include TPF – Docetaxel (Taxotere), Cisplatin (Platinol), and Fluorouracil. Drugs in the phase III clinical pipeline for SCCHN include Avelumab, Durvalumab, Gilotrif/Giotrif (afatinib), Multikine (leukocyte interleukin), Tremelimumab, and Yervoy (ipilimumab). The immune checkpoint inhibitors (durvalumab, tremelimumab, ipilimumab and avelumab) are expected to obtain approval by 2021. However, none of these products are specifically targeting HRAS mutations.
Finances: The company recently underwent a public offering of common stock on July 2, 2018 in which the company sold an aggregate of 4,600,000 shares of common stock at a price of $16.75 per share. Net proceeds from the public offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $74.5 million. This Q2 2018, the company posted R&D expenses of $11.5 million, more than double that of Q2 2017 and a 50% increase in administrative expenses. The net los for the quarter was $14.7 million, or $0.45 per share, again more than double the loss of last year, but only a $0.05 loss per share due mostly to the dilution which occurred this past July. Kura does have cash and cash equivalents which total $200.4 million due to the raise in capital form the offering, which will allow the company to have enough cash to fund current operations through 2021. Thankfully for investors, this means that they do not plan on diluting any time soon. I would however likely expect a dilution in about a year, around the same time they did this year just to keep the cash on hand at a high level.
Review: This company looks promising. This product has a decently sized market that is expected to grow at over 20% for the next 5 years. That is an astounding number that provides a great opportunity for Kura to fill an unmet need. The stock has been trading between $14 and $24 through 2018, and is settled right now at a good support level of $16.75. It has traded down this past month after posting an earnings loss and following the dilution, however I see a turn around coming.
With the high amount of cash on hand and updated data coming out as they present at the ESMO as well as initiating a Phase III study in coming weeks/months, you will see a pop in price here. This company might be a great long-term hold, as they are producing a product that will fill an unmet need, however success at the end of the road is not guaranteed. Oncology drugs that pass Phase I have only shown a likelihood of approval of 5%, compared to an average of 12% for all other indications outside of oncology.
Short term, Phase II data is really showing safety. I see that survival rates for HNSCC are low, incident rates are high, and this drug is well tolerable. I think Phase II will see success and going into Phase III you will see a price increase. Results from Phase III however is a different story. My play here would be a short to medium term investment for now. Their flagship drug has 4 indications that seem to have high potential as well as two other candidates in their pipeline. There will be activity over the next year and with the volatility and price range that this stock sees, I think anything around $16 would be a good buy as we will likely see $22 before the start of 2019.
TLDR
Looks like a good buy under $17 for a swing play up to at least $20. Long term iffy, oncology doesnt have a high rate of approval from the FDA, but there is an unmet market need this company fills. With 3 drugs and 6 drug indications, they have potential to continue to rise. Recently diluted shares, have cash to last 3 years, they should be a great buy here and hold for a few months to maybe a year.
Recently had a PET scan. Do I need to be concerned?
Good day and Merry Christmas. I received from my doctor today the results of a radiological PET Scan following a CT scan showing nodules in my lungs around 20mm. She insists that while the test is inconclusive, she is referring me to an lymphoma oncologist for biopsy. 1) Is this necessary and 2) Based on your experience with similar scan results, do I have something serious to start worrying about here?
I've copy/pasted anonymized scan results along with the questionnaire from the pinned thread in this forum.
Thanks for any advice.
----
Age - 41
Sex - M
Height - 5'10"/178cm
Weight - 265lb/120kg
Race - Caucasian
Any existing diagnosed medical issues (if any) - Asthma, chronic bronchitis, ED
Current medications and doses (if any) - Ventolin (As needed), Advair (2x/day), Sildenafil (for ED as needed), Descovy 200-25mg (1x/day), Cetirizine 25mg (1x/day)
Drug Use (including usage of marijuana) (if any) - None
Smoking Status - 20 year smoker (Age 13-33). Currently using nicotine by vaping.
Duration of complaint - Since adolescence
Issue you're having (be as detailed as possible) - Chronic, non-productive, deep chest cough, with only occasional thin sputum. Seasonally and with colds, cough will generate bloody discharge and large amounts of dark mucus. Generally, lungs are very sensitive to irritants. Written off as "smoker's cough" when an active smoker, and no dramatic change when a non-smoker for 5 years or during the last 3 years as a vaper.
INDICATION: Recent CT chest demonstrating mediastinal lymphadenopathy and pulmonary nodules.
TECHNIQUE: Radiopharmaceutical: 18F fluorodeoxyglucose (FDG), 15.6 millicuries intravenously via left antecubital vein. Blood glucose at time of 18F-FDG injection: 89 mg/dL. Time from 18F-FDG injection to scan: 60 minutes. PET/CT images acquired from skull base through the upper thighs; CT images acquired using a low tube current technique without oral or intravenous contrast for attenuation correction, anatomic localization, and image fusion. 3-D MIP PET images as well as sagittal, coronal and axial 2-D PET, CT and fused PET/CT images were also obtained.
COMPARISON: 12/6/2019 CT chest (attached as well, below).
PET-CT FINDINGS: HEAD/NECK: Significant tonsillar uptake, symmetric, likely physiologic. No suspicious uptake within the neck. No enlarged lymph nodes. Nonenlarged and non hypermetabolic thyroid gland.
CHEST: metabolic uptake: Multifocal FDG avid lymphadenopathy throughout the mediastinum and hilar structures. There are pretracheal, subcarinal enlarged FDG avid lymph nodes measuring up to 2 cm, 7.6 SUV. Bulky bilateral FDG avid hilar lymphadenopathy maximal 9.1 SUV. Additional non-FDG avid pretracheal lymph nodes. lungs: Redemonstrated are multiple pulmonary nodules a few which demonstrate minimal metabolic uptake up to 1.8 SUV. Combination of mediastinal/hilar disease with pulmonary nodules raises greatest concern for malignancy including metastatic lung cancer lymphoma. However, inflammatory processes (such as sarcoidosis) cannot be excluded. Correlation suggested. Mediastinum: No aortic aneurysm. heart: No cardiomegaly or pericardial effusion. chest wall: No chest wall mass.
ABDOMEN: metabolic uptake: No suspicious metabolic uptake. nodes: No enlarged lymph nodes. Solid organs: Liver, spleen, adrenal glands and kidneys unremarkable. Gallbladder unremarkable.
PELVIS: metabolic uptake: No suspicious metabolic uptake. nodes: No enlarged lymph nodes. Solid organs: Bladder and reproductive organs unremarkable..
MUSCULOSKELETAL: Skeletal structures are unremarkable for age.
IMPRESSION: 1.Diffuse FDG avid bulky mediastinal and bilateral hilar adenopathy (maximal diameter 3 cm ; 9.1 SUV max), along with a few small bilateral pulmonary nodules the latter which are minimally FDG avid. Similar findings seen on the recent CT study. Findings most concerning for metastatic disease. Other etiologies including inflammatory disease cannot be entirely excluded. 2. No further mass, adenopathy or suspicious metabolic uptake noted. EORTC Response Criteria: Complete metabolic response: Max SUV <2.5 or equivalent to background. Partial metabolic response: Decrease in Max SUV >/= 25%. Progressive metabolic disease: Increase in Max SUV > 25%. Stable metabolic disease: Change in Max SUV < 25%.
Results of CT scan 12/6/19:
TECHNIQUE: Contiguous transaxial images obtained of the thorax. No IV contrast. Multiplanar coronal and sagital reconstruction images obtained. COMPARISON: 8/23/2019 abdomen pelvic CT scan.
FINDINGS: Thoracic inlet: Unremarkable. Mediastinum: No enlarged mediastinal lymph nodes involving the pretracheal, prevascular and subcarinal locations. Enlarged hilar lymph nodes. Heart: Unremarkable. Lungs: Multiple bilateral pulmonary nodules measuring up to 16 mm to which were noted at the right lung base on the prior study. Limited visualization of the upper abdomen demonstrates no definite abnormality . It must be stressed that a complete abdomen survey was not performed at this time. Bone windows demonstrate No fracture or destructive lesion.
IMPRESSION: 1. There are enlarged mediastinal and hilar lymph nodes along with disseminated pulmonary nodules. Findings compatible with metastatic disease until proven otherwise. Primary source uncertain. 2. Otherwise no lung infiltrate, pleural effusion or central airway lesion.
submitted by killians1978 to medical [link] [comments]
Sàn tiền ảo nào uy tín nhất 2021 trong thị trường trade Coin
Với trường hợp các sàn Forex lừa đảo nhiều như hiện nay trên thị trường thì việc chọn lựa được sàn Forex uy tín là điều thiết yếu nhất cho các người nào đầu cơ vào kênh này. Do vậy bản thân những nhà đầu tư, đặc thù là người mới cần phải biết rõ và nắm các kiến thức cơ bản để việc đầu cơ hiệu quả, chuyên nghiệp hơn. Và để có thông tin về các sàn Forex thì không nên bỏ lỡ Phân tích
sàn tiền ảo nào uy tín mà Infofinance.vn giới thiệu dưới đây.
Thực trạng sàn Forex lừa đảo hiện nay
Hiện nay kế bên các sàn phân phối Forex uy tín, sàn Forex hoạt động có giấy phép thì có rất nhiều sàn phân phối lừa đảo, làm giả giấy phép hoạt động dưới mọi hình thức để đi lừa đảo. Và vấn đề này ngày càng đa dạng, những dụng cụ truyền thông liên tiếp cảnh báo và sắm ra những sàn này để mọi người có thể tránh xa.
Phương thức lừa đảo của những sàn thực ra rất dễ nhận diện, đa số các sàn mới mà hoạt động theo hiểu mở hội thảo, đi lôi kéo người người kia tham dự vào sàn. Và mọi người quan tâm khi mà đi vào một hội thảo giới thiệu về sàn, về đầu cơ tiền ảo hay Forex nào ấy là cốt yếu là người già, sinh viên, phụ nữ…thì chuẩn xác tầm 80% là sàn đang có vấn đề. Bởi các sàn chuyên nghiệp họ khi công ty hội nghị là để giới thiệu về Công trình nào đó mà thôi và được tiến hành rất chuyên nghiệp.
📷
Sàn XTB
Sàn XTB ra đời trong khoảng năm 2002, là nhà môi giới ngoại ăn năn Đầu tiên tại Ba Lan, hiện là sàn phân phối Forex hàng đầu thị phần. Sàn được cấp giấy phép Cơ quan quản lý cấp phép bởi FCA (Anh), CySec (Cyprus), KNF (Ba Lan), IFSC ( Belize) và XTB có 13 văn phòng thế giới, bao gồm: Anh, Ba Lan, Đức, Pháp và Chile.
Như thế nên xét về độ uy tín và an toàn thì XTB luôn nằm trong top đầu Đánh giá của thị trường, kế bên sản xuất các sản phẩm Forex thì sàn còn cung ứng nhiều sản phẩm đàm phán khác như chỉ số, vàng, kim loại, tiền ảo, cổ phiếu. XTB được niêm yết trên sàn chứng khoán Warsaw (Ba Lan) với tên phần đông là X-Trade Brokers Dom Maklerski SA, bảo đảm tính minh bạch về tài chính.X
xem thêm :
cách nạp tiền sàn CoinEx thông báo về sàn:
Đòn bẩy
1:500
có mặt trên thị trường
2002
Giấy phép
FCA (Anh), CySec (Cyprus), KNF (Ba Lan), IFSC ( Belize)
Khớp lệnh
Sàn ECN, Non-Dealing Desk
nền tảng thương lượng
MT4, xStation5
Ưu điểm đàm phán Forex tại sàn XTB:
- Có hỗ trợ tiếng Việt cho người giao dịch
- tổ chức có giấy phép hoạt động của cơ quan điều hành bậc nhất, bảo đảm uy tín và an toàn
- Đòn bẩy phân phối nhàng nhàng ko quá cao tránh được khả năng rủi ro
- nền tảng thương lượng tương thích đa dạng trang bị, thương lượng lâu bền và an toàn
- không tính phí đàm phán và hoả hồng
- tương trợ nạp và rút tiền chóng vánh, đơn giản qua ứng dụng tiền ảo phổ thông lênh. Nạp tiền ngay thức thì và rút tiền trong ngày.
tuy thế với sàn XT thì ko có tương trợ CopyTrade và PAMM/MAM, hiện nay chỉ sản xuất 1 account độc nhất nên người mới hay chuyên nghiệp cũng sẽ thương lượng cùng 1 account sẽ gây cạnh tranh và bất luôn thể cho nhà đầu tư ít kinh nghiệm.
Sàn IC Markets
IC Markers là sàn phân phối tới từ Úc, ra đời vào năm 2007 và được cấp phép bởi các cơ quan điều hành như ASIC, FSA. Sàn IC Markets hoạt động trung gian kết nối theo mô phỏng Non Dealing Desk, tức là sẽ kết nối nhà đầu tư với đối tác thanh khoản tiền tệ như ngân hàng, tổ chức tín dụng nên ko có trường hợp ấp ủ lệnh hay bấ kỳ vấn đề gì.
Về ưu điểm lúc đàm phán Forex sàn ICMarkets:
- Sàn có thời kì hoạt động lâu, có giấy phép của công ty bậc nhất nên an toàn và uy tín
- Sàn cung cấp phí đàm phán từ 0 pip, lợi cho nhà đầu tư dài hạn
- phân phối hơn 65 cặp tiền tệ, các đồng tiền to và phổ thông nhất
- Tính thanh khoản sâu trong khoảng các đối tác thanh khoản lớn và bậc nhất
- tương trợ nạp và rút tiền với đa dạng phương thức miễn phí
- thời gian đàm phán nạp tiền lập tức, rút tiền trong ngày
- tương trợ thương lượng chóng vánh
tuy thế thủ tục mở tài khoản của sàn tương đối phức tạp và mất nhiều thời gian, với cá nhân mới thì gặp phổ thông cạnh tranh. Đây là sàn giao dịch thích hợp cho các nhà đầu cơ có kinh nghiệm, số tiền tối thiểu tương đối cao lúc đàm phán.
Sàn XM
XM ra đời từ năm 2009 tại Síp và Úc, là thành viên của Trading Point of Financial Instruments UK Ltd – một doanh nghiệp lớn ở Vương Quốc Anh. Có hội sở hoạt động tại Síp và Úc, nơi có đa dạng sàn môi giới uy tín đang hoạt động. XM được những cơ quan quản lý cấp phép hoạt động FCA (Anh), CySEC (Síp), ASIC (Úc), IFSC (Belize).
Về ưu điểm khi giao dịch Forex sàn XM
- Sàn ra đời lâu năm, có phổ thông người tham gia, có phần lớn giấy phép => Uy tín
- Sàn hỗ trợ đàm phán phí từ 0 pip, tương đối thấp
- Tiền nạp tối thiều thấp chỉ trong khoảng 50$
- Sàn đều đặn có chương trình thưởng: Bonus 30$ lúc mở account, có chương trình tặng 15$ khi nạp tiền thương lượng lần đầu…
- Đòn bẩy sàn cung ứng cao
- sản xuất hơn 55 cặp tiền tệ hàng đầu toàn cầu
- đàm phán ko ẩn phí
- Tính thanh khoản cao bởi kết nối đa dạng nhà thanh khoản hàng đầu toàn cầu
tuy nhiên vẫn còn một vài điểm cần chú ý lúc giao dịch Forex trên sàn XM ấy là mở tài khoản mất hơi nhiều thời kì và quy trình hơi phức tạp.
Sàn Exness
xây dựng thương hiệu trong khoảng năm 2008, cho đến nay sàn Exness đã xây dụng được thương hiệu cho bản thân mình. Có hội sở hoạt động tại Síp, được những cơ quan điều hành như FCA, CySEC, FSA cấp phép hoạt động. Đây là một trong những đại lý phân phối Forex lớn, mang tới phổ biến giải thưởng từ những công ty bậc nhất thế giới như tạp chí World Finance Media.
Về ưu điểm khi giao dịch Forex sàn Exness:
- giấy má pháp lý, hạ tầng luật pháp của sàn đều số đông, nên tương đối uy tín và an toàn cho nhà đầu tư.
- đại lý phân phối hỗ trợ tiếng Việt
- cung cấp 107 cặp tiền tệ, bao gồm cả những cặp tiền hi hữu gặp nhất
- nền tảng giao dịch chóng vánh, linh hoạt và an toàn
- Phí thương lượng thấp
- Phương thức nạp và rút tiền phổ quát, thời kì xử lý chóng vánh trong ngày
- hỗ trợ tiếng Việt trong thời kỳ giao dịch, xử lý vấn đề
Chính vì thế ví như để đầu cơ Forex, muốn tậu tới nơi có phổ biến cặp tiền nhất thì vững chắc mọi người phải chọn Exness.
Sàn Avatrade
Avatrade xây dựng thương hiệu từ năm 2006 tại Ireland, là một đại lý phân phối Forex hàng đầu thị phần hiện nay. Được cấp phép bởi các cơ quan điều hành hàng đầu toàn cầu :
- nhà băng Trung ương Ireland
- Ủy ban nhà sản xuất tài chính BVI trên Quần đảo Virgin thuộc Anh
- Ủy ban Chứng khoán và đầu tư Úc ( ASIC )
- Cơ quan điều hành Khu vực nguồn vốn (FSCA) ở Nam Phi
- Cơ quan dịch vụ vốn đầu tư Nhật Bản (FSA)
- Hiệp hội tương lai vốn đầu tư Nhật Bản (FFAJ)
Ưu điểm thương lượng của sàn Avatrade
- Sàn hoạt động lâu năm, có đa số hồ sơ hạ tầng pháp lý hoạt động => uy tín, an toàn
- Phí đàm phán thấp
- không tính phí nạp và rút tiền
- tương trợ chóng vánh, dụng cụ giáo dục đầy đủ và chi tiết
- Mở tài khoản mau chóng, tiện dụng
- nền móng thương lượng linh động
- phân phối với hơn 60 cặp tiền đa dạng và tương trợ với 5 đồng bạc Fiat
- tăng ngay tiền thưởng lên đến 10.000 đô la Mỹ khi mở account và đàm phán lần
tuy vậy sàn vẫn có 1 vài tránh được mọi người cần quan tâm đấy là: phương tiện nghiên cứu còn kém, tương trợ qua điện thoại chậm và không linh hoạt, điều hành account mất phí và ko hoạt động cũng mất phí.
📷
Sàn CMTrading
CMTrading là nhãn hàng hoạt động dưới sự điều hành của BLACKSTONE Marketing SA (PTY) LTD. Công ty này là một trong các nhà môi giới ngoại hối hận thông minh nhất toàn cầu và là nhà môi giới to nhất ở Nam Phi. CM được điều hành bởi FSCA ở Nam Phi và có trụ sở chính tại Seychelles. Được nhận phổ biến giải thưởng, nổi trội là Nhà môi giới vốn đầu tư tốt nhất ở Châu Phi 2019 và 2020.
Ưu điểm đàm phán Forex sàn CMtrading:
- sản xuất hơn 28 cặp tiền để đàm phán
- tài khoản được tư nhân quản lý
- xây dựng thương hiệu từ năm 2011, có giấy phép của FSCA
- sản xuất account đàm phán với phổ biến sự lựa chọn
- cung cấp hệ thống giáo dục đông đảo, chuyên nghiệp và chi tiết nhất
- tương trợ chóng vánh
- nền móng thương lượng thị trấn hội và sao chép
- những công cụ phân tích thị trường hoạt động tốt, đưa ra những dấu hiệu tốt
tuy thế sàn này ko được quy định bởi FCA, ngôn ngữ tương trợ tránh được và hoạt động phần lớn ở nước ngoài ko hoạt động ở Việt Nam.
Để biết được đâu là sàn giao dịch tiền ảo phù hợp với bạn, hãy xem thêm tại bài viết về
các loại tiền ảo tiềm năng mà chúng tôi đã tổng hợp
Fusion Markets Review
Fusion Markets is an Australian licensed MT4 Forex broker, that opened in 2019.
Our review of Fusion Markets find that investors can trade on the industry standard MT4 trading platform. They offer the full suite of MetaQuotes trading software including; Metatrader 4 Desktop, WebTrader, Mobile Apps, Multi Account Manager (MAM/PAMM) and Virtual Private Server (VPS).
The range of underlying assets available for trading CFD’s are: Forex, Energy, Precious Metals, Crypto Currencies and Commodities.
Read the rest of the Fusion Markets Review submitted by laurabel to ScamBroker [link] [comments]
Clarification of PET Scan, Please
Good day and Merry Christmas. I received from my doctor today the results of a radiological PET Scan following a CT scan showing nodules in my lungs around 20mm. She insists that while the test is inconclusive, she is referring me to an lymphoma oncologist for biopsy. 1) Is this necessary and 2) Based on your experience with similar scan results, do I have something serious to start worrying about here?
I've copy/pasted anonymized scan results along with the questionnaire from the pinned thread in this forum.
Thanks for any advice.
----
Age - 41
Sex - M
Height - 5'10"/178cm
Weight - 265lb/120kg
Race - Caucasian
Any existing diagnosed medical issues (if any) - Asthma, chronic bronchitis, ED
Current medications and doses (if any) - Ventolin (As needed), Advair (2x/day), Sildenafil (for ED as needed), Descovy 200-25mg (1x/day), Cetirizine 25mg (1x/day)
Drug Use (including usage of marijuana) (if any) - None
Smoking Status - 20 year smoker (Age 13-33). Currently using nicotine by vaping.
Duration of complaint - Since adolescence
Issue you're having (be as detailed as possible) - Chronic, non-productive, deep chest cough. Seasonally and with colds, cough will generate bloody discharge and large amounts of dark mucus. Generally, lungs are very sensitive to irritants. Written off as "smoker's cough" when an active smoker, and no dramatic change when a non-smoker for 5 years or during the last 3 years as a vaper.
INDICATION: Recent CT chest demonstrating mediastinal lymphadenopathy and pulmonary nodules.
TECHNIQUE: Radiopharmaceutical: 18F fluorodeoxyglucose (FDG), 15.6 millicuries intravenously via left antecubital vein. Blood glucose at time of 18F-FDG injection: 89 mg/dL. Time from 18F-FDG injection to scan: 60 minutes. PET/CT images acquired from skull base through the upper thighs; CT images acquired using a low tube current technique without oral or intravenous contrast for attenuation correction, anatomic localization, and image fusion. 3-D MIP PET images as well as sagittal, coronal and axial 2-D PET, CT and fused PET/CT images were also obtained.
COMPARISON: 12/6/2019 CT chest (attached as well, below).
PET-CT FINDINGS: HEAD/NECK: Significant tonsillar uptake, symmetric, likely physiologic. No suspicious uptake within the neck. No enlarged lymph nodes. Nonenlarged and non hypermetabolic thyroid gland.
CHEST: metabolic uptake: Multifocal FDG avid lymphadenopathy throughout the mediastinum and hilar structures. There are pretracheal, subcarinal enlarged FDG avid lymph nodes measuring up to 2 cm, 7.6 SUV. Bulky bilateral FDG avid hilar lymphadenopathy maximal 9.1 SUV. Additional non-FDG avid pretracheal lymph nodes. lungs: Redemonstrated are multiple pulmonary nodules a few which demonstrate minimal metabolic uptake up to 1.8 SUV. Combination of mediastinal/hilar disease with pulmonary nodules raises greatest concern for malignancy including metastatic lung cancer lymphoma. However, inflammatory processes (such as sarcoidosis) cannot be excluded. Correlation suggested. Mediastinum: No aortic aneurysm. heart: No cardiomegaly or pericardial effusion. chest wall: No chest wall mass.
ABDOMEN: metabolic uptake: No suspicious metabolic uptake. nodes: No enlarged lymph nodes. Solid organs: Liver, spleen, adrenal glands and kidneys unremarkable. Gallbladder unremarkable.
PELVIS: metabolic uptake: No suspicious metabolic uptake. nodes: No enlarged lymph nodes. Solid organs: Bladder and reproductive organs unremarkable..
MUSCULOSKELETAL: Skeletal structures are unremarkable for age.
IMPRESSION: 1.Diffuse FDG avid bulky mediastinal and bilateral hilar adenopathy (maximal diameter 3 cm ; 9.1 SUV max), along with a few small bilateral pulmonary nodules the latter which are minimally FDG avid. Similar findings seen on the recent CT study. Findings most concerning for metastatic disease. Other etiologies including inflammatory disease cannot be entirely excluded. 2. No further mass, adenopathy or suspicious metabolic uptake noted. EORTC Response Criteria: Complete metabolic response: Max SUV <2.5 or equivalent to background. Partial metabolic response: Decrease in Max SUV >/= 25%. Progressive metabolic disease: Increase in Max SUV > 25%. Stable metabolic disease: Change in Max SUV < 25%.
Results of CT scan 12/6/19:
TECHNIQUE: Contiguous transaxial images obtained of the thorax. No IV contrast. Multiplanar coronal and sagital reconstruction images obtained. COMPARISON: 8/23/2019 abdomen pelvic CT scan.
FINDINGS: Thoracic inlet: Unremarkable. Mediastinum: No enlarged mediastinal lymph nodes involving the pretracheal, prevascular and subcarinal locations. Enlarged hilar lymph nodes. Heart: Unremarkable. Lungs: Multiple bilateral pulmonary nodules measuring up to 16 mm to which were noted at the right lung base on the prior study. Limited visualization of the upper abdomen demonstrates no definite abnormality . It must be stressed that a complete abdomen survey was not performed at this time. Bone windows demonstrate No fracture or destructive lesion.
IMPRESSION: 1. There are enlarged mediastinal and hilar lymph nodes along with disseminated pulmonary nodules. Findings compatible with metastatic disease until proven otherwise. Primary source uncertain. 2. Otherwise no lung infiltrate, pleural effusion or central airway lesion.
submitted by killians1978 to medical_advice [link] [comments]
Netcurrencyindex IEO starts soon
 | https://preview.redd.it/l4y6xvep48g31.png?width=745&format=png&auto=webp&s=ac688a9a4feb95591e4153dff9afd152cbfbfbab Dear traders, IEO for Netcurrencyindex Benchmark Token starts on August 15. Netcurrencyindex with the help of its indices and extensive features has become the standard for measuring the cryptocurrency market and associated blockchain industry sector in the best possible way. NCIgo app is a combination of Social trading for Pamm and Copy trading to earn on your followers and robust Futures Exchange for Crypto Derivates with the integrated possibility to use the NCIbot for automatic trading. which helps anyone to trade the portfolio in an automated and hassle-free environment. Netcurrencyindex with its NCIgo app has been currently selected as The Innovator and Best Investment Project 2019 for its past and upcoming achievements of more than 120,000 users. More information in the following news https://news.p2pb2b.io/netcurrencyindex-ieo-starts-soon-2/ |
Nearly everyone living in Alaska gets about $2,000 a year from the state’s $65 billion fund. We asked 9 Alaskans how they spend it.
- Larry Hall, pictured here in 1973 with his son, no longer lives in Alaska, but was there for the creation of the permanent fund in 1976 and the first dividend payment in 1982.
- Terry G. used his dividend to build a log cabin.
- Melodey Martindale is a lifelong Alaskan who has spent her adult life using the PFD solely to pay bills and buy food.
- Nathan Zierfuss-Hubbard, pictured here with his wife Pamm, moved to California in 2017, but he's used the PFD for assistance in all stages of life.
- Karina Packer has used the PFD to pay off student loans and build a savings account. She used last year's PFD to buy a puppy.
- Scott Maxwell has received the PFD for four years, and it helps him visit his family on the East Coast.
- Christopher Wright and his wife have spent decades as rural Alaskans and use their dividend to keep their home heated and in good shape for the winter.
- Jordan Iverson used her dividends to pay for college and then get an apartment after graduation.
- Daniel Helmer, pictured here with his dog Galena, and his wife use the dividend to stock up on fuel and food before winter cuts them off from the rest of Alaska.
Link to article Ruslan Kamenskiy - Genesis Vision CEO - did you know this?
How much do you know about the GV CEO Ruslan?
He is an extremely experienced developer with a HUGE proven track record:
- Software developer @ Tools 4 brokers -> Development for the trading platform MetaTrader, multithreaded and server applications, cross-platform applications.
- Head Software developer for Forex broker -> Managing and tech leading the development of the site and the trading platform. Included a large web service for exchange Forex services (tournaments, PAMM, signals, diaries of traders, etc.).
- Principle software developer - SAINT PETERSBURG STOCK EXCHANGE -> Development of the massive ASP MVC / Angular application for holding tenders and auctions in electronic form. Business logic included the calculation of prices, the life cycle of purchases and applications, signing of EDS actions.
- Senior Backend Developer - Epam Systems -> Building the SaaS solution for processing data and investment analysis of private equity. The product offers users a web portal (ASP.NET), a client application (.NET based), a public WCF service and an iPad application with real-time calculations.
- Software Engineer - QuantBrothers -> - Development of the concept of a distributed organization economy based on the blockchain
TALK ABOUT LEADING BY EXAMPLE.
Right now the Genesis Vision team are quiet, working away, with this guy spear heading the team. I am an early investor in GVT, before it was as successful and hyped as right now. I invested because of many reasons, I would need another thread to discuss them all. However amongst these many reasons, 1 of them was because of this guy, highly experienced, proven track record, I can quite happily say I trust them with my money and GVT.
2018 & 2019 will be HUGE for GVT ~ big things coming!
Geco.one token’s purchase at Private Sale guarantees the lowest price, the Private Sale is on now, and it ends on 31st June 2019. Next, they begin the IEO sale for 0.35 € – 0.45 € on 1st July 2019. Active trading of GEC on the COINEAL and LATOKEN starts the day after the IEO’s are over
Why should people take part in Geco.one’s IEO?
Looking at the BNB example shows precisely the enormous potential of Geco.one project. We will debut our GEC token on the 1st July 2019 on two cryptocurrency exchanges – COINEAL and LATOKEN – right after the IEO’s are over. The exchanges mentioned above have a daily volume ranging from $1-2 billion.
Geco.one burns tokens each time they get utilised on the platform. This supply deflation helps the token to retain value. Thus, the GEC’s token supply continuously decreases alongside hopefully increased demand. Thanks to similar utilisation process, the BNB Coin saw such a sharp rise and at Geco.one we take a leaf out of their book as well as introducing PAMM accounts to the cryptocurrency market. We hope to see quick growth and a market capitalisation worthy of the biggest cryptocurrencies as soon as possible.
The interest in cryptocurrencies is increasing at a fantastic rate. We just need to look at the many large companies who previously showed no interest in cryptocurrency, now bringing their own digital coins to the market as confirmation. Therefore if you want to keep up with the rapidly growing market and the investment opportunities it gives, make use of its potential with Geco.one.
GEC token’s purchase at Private Sale guarantees the lowest price. The Private Sale is on now, and it ends on 31st June 2019. Next, we begin the IEO sale for 0.35 € – 0.45 € on 1st July 2019. Active trading of GEC on the COINEAL and LATOKEN starts the day after the IEO’s are over.
The owner of Geco.one is a company registered in Estonia (Geco One OU). It is licensed and authorised by Estonian Financial Intelligence Unit (FIU) to provide virtual currency exchange services and for the creation of virtual currency wallets.
Don’t let this fantastic investment opportunity pass you by!
submitted by hoshsolomun to InitialCoinOfferings [link] [comments]
Sàn giao dịch tiền điện tử Bitcoin, ETH, KRS
Vào tháng 7 năm 2019, nền tảng giao dịch tiền điện tử, bitcoin, eth, krs TimeBitex dưới sự quản lý của TimeBit Pte đã chính thức được thành lập tại Singapore. TimeBitex đã tập hợp các kỹ sư công nghệ hàng đầu thế giới để thành lập nhóm phát triển của mình, và sử dụng ngôn ngữ Golang bằng cách tuân thủ tư duy định hướng công nghệ đổi mới của mình về một bước tiến nhỏ trong công nghệ - một bước tiến lớn trong nền tảng. Là một nền tảng giao dịch tiền điện tử bitcoin, eth, krs, TimeBitex cung cấp dịch vụ của giao dịch tiền tệ fiat, giao dịch tiền điện tử, ký quỹ đòn bẩy, giao dịch sao chép xã hội PAMM cũng như dẫn đầu nền tảng với mô hình trao đổi đám mây toàn cầu tiên phong. ---------------------------- Xem thêm video Tiếng Việt liên quan:
https://bit.ly/39BZa51 --Hướng dẫn lập tài khoản trên sàn giao dịch tiền điện tử Timebit:
https://bit.ly/3ayd9sK --Hướng dẫn nạp tiền vào sàn giao dịch tiền điện tử TimeBit để kiếm lời an toàn :
https://bit.ly/2IvH2ht Investor dictionary
 | Investment portfolio - a set of investment instruments that are combined into a single list. It is necessary to account for and minimize the risk of capital loss. https://preview.redd.it/f7artop4d1n21.jpg?width=1000&format=pjpg&auto=webp&s=4f2966927b715d15d476813aa0488ac00323263b Investment funds are projects where a lot of investors, through the website of the fund, use payment systems, contribute money to the project's account, where professional traders deal with them. PAMM-account is an investment tool that serves to simplify the transfer of money from an investor to a manager. When working with PAMM-accounts, you can get a yield of 5 to 100% per month. PAMM-account graph reflects the nature and behavior of the person who stands behind him. Understanding at what level of development a trader is, one can predict his behavioral responses, and hence the periods of greatest profitability. Reinvestment - re-investment of funds or profits for a larger increase in previously invested investments. Reinvestment is: daily, weekly, once a month Compound interest is the accrual of interest on interest, i.e. interest is charged not only on the initial contribution, but also on the profit accrued in the previous period. For example, you have invested $ 100 in an investment company or a PAMM account whose average return is 5% per month. In the first month you will receive 100 x 0.05 = $ 5. In the second month, your gain will be (100 + 5) x 0.05 = 5.25. In the third (100 + 5 + 5.25) x 0.05 = 5.5125, etc. Trust management is the transfer of assets to a trustee, so that he invests your money at his discretion in order to make a profit. All income received will be divided between you and the manager in a certain ratio, according to the offer. Today I’m interested in the BitTeam VTT cryptocurrency investment tool. And I already have a few coins At the moment, the BTT token costs $ 0.6, and just a week ago it was $ 0.4. Estimated cost -1 $, by September-October 2019 80% of tokens will be sold and eventually redeemed and burned. 20% will be distributed to the team, advisors and the PR company. Perhaps this is the best investment offer on the market. Sign up for FREE BitTeam #BitTeam #BTT #tokensale #P2P #exchange #Marketplace |
GEC token’s purchase at Private Sale guarantees the lowest price and the Private Sale is on now, and it ends on 31st June 2019. Next, they begin the IEO sale for 0.35 € – 0.45 € on 1st July 2019
Why should people take part in Geco.one’s IEO?
Looking at the BNB example shows precisely the enormous potential of Geco.one project. We will debut our GEC token on the 1st July 2019 on two cryptocurrency exchanges – COINEAL and LATOKEN – right after the IEO’s are over. The exchanges mentioned above have a daily volume ranging from $1-2 billion.
Geco.one burns tokens each time they get utilised on the platform. This supply deflation helps the token to retain value. Thus, the GEC’s token supply continuously decreases alongside hopefully increased demand. Thanks to similar utilisation process, the BNB Coin saw such a sharp rise and at Geco.one we take a leaf out of their book as well as introducing PAMM accounts to the cryptocurrency market. We hope to see quick growth and a market capitalisation worthy of the biggest cryptocurrencies as soon as possible.
The interest in cryptocurrencies is increasing at a fantastic rate. We just need to look at the many large companies who previously showed no interest in cryptocurrency, now bringing their own digital coins to the market as confirmation. Therefore if you want to keep up with the rapidly growing market and the investment opportunities it gives, make use of its potential with Geco.one.
GEC token’s purchase at Private Sale guarantees the lowest price. The Private Sale is on now, and it ends on 31st June 2019. Next, we begin the IEO sale for 0.35 € – 0.45 € on 1st July 2019. Active trading of GEC on the COINEAL and LATOKEN starts the day after the IEO’s are over.
The owner of Geco.one is a company registered in Estonia (Geco One OU). It is licensed and authorised by Estonian Financial Intelligence Unit (FIU) to provide virtual currency exchange services and for the creation of virtual currency wallets.
Don’t let this fantastic investment opportunity pass you by!
submitted by DangerousBoard to InitialCoinOfferings [link] [comments]
Geco.one will debut GEC token on the 1st July 2019 on two cryptocurrency exchanges – COINEAL and LATOKEN – right after the IEO’s are over and the exchanges mentioned above have a daily volume ranging from $1-2 billion.
Why should people take part in Geco.one’s IEO?
Looking at the BNB example shows precisely the enormous potential of Geco.one project. We will debut our GEC token on the 1st July 2019 on two cryptocurrency exchanges – COINEAL and LATOKEN – right after the IEO’s are over. The exchanges mentioned above have a daily volume ranging from $1-2 billion.
Geco.one burns tokens each time they get utilised on the platform. This supply deflation helps the token to retain value. Thus, the GEC’s token supply continuously decreases alongside hopefully increased demand. Thanks to similar utilisation process, the BNB Coin saw such a sharp rise and at Geco.one we take a leaf out of their book as well as introducing PAMM accounts to the cryptocurrency market. We hope to see quick growth and a market capitalisation worthy of the biggest cryptocurrencies as soon as possible.
The interest in cryptocurrencies is increasing at a fantastic rate. We just need to look at the many large companies who previously showed no interest in cryptocurrency, now bringing their own digital coins to the market as confirmation. Therefore if you want to keep up with the rapidly growing market and the investment opportunities it gives, make use of its potential with Geco.one.
GEC token’s purchase at Private Sale guarantees the lowest price. The Private Sale is on now, and it ends on 31st June 2019. Next, we begin the IEO sale for 0.35 € – 0.45 € on 1st July 2019. Active trading of GEC on the COINEAL and LATOKEN starts the day after the IEO’s are over.
The owner of Geco.one is a company registered in Estonia (Geco One OU). It is licensed and authorised by Estonian Financial Intelligence Unit (FIU) to provide virtual currency exchange services and for the creation of virtual currency wallets.
Don’t let this fantastic investment opportunity pass you by!
submitted by abubakarbes9 to CryptocurrencyICO [link] [comments]
[ICO][IEO] Geco.one to debut with its GEC token on Coineal and Latoken
Geco.one is a global
trading PAMM platform that allows the cryptocurrency trading with the usage of Futures Trading which enables concluding short and long positions on crypto assets using leverage. Its flagship service, called
PAMM account, allows you to invest in cryptocurrency pairs by entrusting your resources to experienced traders as well as providing you with all the tools necessary to become a crypto-trader yourself. Geco.one, as one of the first platforms in the world, allows moving verified solutions from
Forex to
Crypto market. Geco.one's
IEO is going to start soon. The IEO sale of
GEC token begins for 0.35 € - 0.45 € on
1st July 2019. Active trading of GEC on the COINEAL and LATOKEN starts the day after the IEO’s are over. There's also opportunity to buy GEC token at
Private Sale. GEC token's purchase at Private Sale guarantees the lowest price.
Private Sale is on now, and it ends on 31st June 2019.
Gecoin is also the name of a cryptocoin (GEC) that will be traded and used on the multiple exchanges. Once the IEO is completed, the value of GEC will rise alongside with the growth of the Geco.one platform. Geco.one burns tokens each time they get utilised on the platform. Thanks to that, the number of GEC's token continuously decreases with simultaneous growth in their value.
For more details, visit:
https://geco.one submitted by Bullbear1990 to CryptocurrencyICO [link] [comments]
News Update - 08.02.18
1) Do you remember the B2BX Roadmap? Of course you do! Our company reputation, White Paper and Roadmap are the aspects most ICO participants pay attention to.
The roadmap for the B2BX ICO included options for action depending on the amount of funds collected.
🔥 Now it's time to present the actual B2BX development plan!
The B2BX Roadmap: https://medium.com/@b2brokeb2broker-past-present-future-f2876c406a7c We marked on the map the most important events for the company, not just plans for 2018-2019, but a short review of the past. The most important events of the future, of course, are obtaining licenses, developing our own technologies and opening offices in strategically important locations on the financial map of the world. All this brings us closer to the moment when B2BX becomes Prime Broker in the market of cryptocurrency liquidity! Full version on Medium.
2) Integration with ONEZERO We ordered the placement on servers of Equinix - LD4. This data center hosts the largest European banks and brokers. Given that B2BX will have a cross-connect with liquidity providers, the speed of obtaining prices from providers and the speed of execution of orders will be as high as possible! New working conditions with OneZero will reduce the cost of services for our customers and increase our attractiveness for new customers. Recall that in B2BX will be able to nominate margin accounts in any currency, including cryptocurrencies.
3) CRYPTOCURRENCY PAYMENT GATEWAY There is also the possibility of accepting a B2B coin with zero commission. We have started integration with 10 merchants and have begun to develop a site for B2B coin, which will accumulate information about all crypto-brokers, exchanges and other customers that will start to accept the B2B coin for payment. As we launch each merchant, we will send out a newsletter. We have also implemented the support of tokens based on Ethereum standard ERC20. Now every merchant can start receiving any token/coin issued on the Ethereum platform. Please note that if you have a website, an online store, a broker company, crypto-exchange or a marketplace, and you want to expand payment methods you should connect B2Broker crypto gateway. To do this, you just need to select the cryptocurrencies from the list that you want to accept (BTC, BCC, ETH, LTC, DASH, XMR, B2B, BTG (bitcoin gold) and hundreds of tokens released on the Ethereum platform), provide purse addresses and make an easy integration with your site. In just an hour your customers will be able to pay for goods or services using cryptocurrency with low commission rates every day, free installation, no monthly fee, no freeze period, no banks and no any third intermediaries.
4) INVESTMENT PLATFORM To date, this product is used by 11 brokers, two of which have become our customers this year. The investment platform allows brokers to popularize cryptocurrency trading products while customers have the opportunity to subscribe to the signals of professional traders and earn. Also for professional traders it is possible to create PAMM accounts or portfolios of cryptocurrencies. The IT department has redesigned the back-end platform to make the MT5 work more stable.
5) Work with clients The B2Broker account department adjusts business processes to improve operational efficiency. For example, improving the interaction with the development department will positively affect the speed of working with customers. Of course, the number of our employees is growing, but we understand that without optimizing business processes, we can not build an effective company! We are expanding the product line and preparing knowledge bases to quickly train employees.
Our clients comprise 72 companies, 25 of which use B2Broker’s cryptocurrency solutions!
The team is also developing new standards of service which will correspond to the status of Prime Broker.
6) PLATFORM FOR ICO To date, our platform for ICO has benefited 4 companies. Of course, all payments go through our crypto gateway leaving these companies to concentrate on their marketing. Such a collaboration has proved its effectiveness. Large ICOs prefer this model, choosing a solution that is ready, tested and constantly updated. A demo version is available by clicking on the link.
Oh, and by the way! This week in Finance Magnates there was a press release about the opening of office in Malaysia.
https://www.financemagnates.com/forex/technology/b2broker-extends-asian-expansion-malaysian-office/ 🔜 In mid-May, a summit on blockchain technology will take place in New York.
https://www.coindesk.com/events/consensus-2018/sponsors/ submitted by b2bx to u/b2bx [link] [comments]
6th February 2019 40 th EORTC-PAMM Winter Meeting 7th – 9 th February 2019 Palazzo della Gran Guardia, piazza Bra Verona - Italy PAMM Board Eric Raymond, France, Chair Annette Larsen, France Elisa Giovannetti, The Netherlands Godefridus J. Peters, The Netherlands Scientific Committee Andrea Bonetti, Italy Brian Leyland-Jones, USA Etienne Chateleut, France Paola Perego, Italy Joseph Ciccolini ... 40th EORTC-PAMM Winter Meeting. 06 Feb - 09 Feb 2019 Verona, IT. Abstract submission (deadline: 20th December 2018) Registration. More information on the conference website. Next events. EORTC Cancer in Elderly Task Force Virtual Meeting. November 13. Head and Neck Young Investigators Group Webinar. November 16. European Cancer Summit 2020. November 19. Free webinar: What is the future of ... Anticancer Res. 2019 Jul;39(7):3419-3422. doi: 10.21873/anticanres.13486. Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Rodallec A(1)(2), Fanciullino R(1)(2), Benzekry S(2)(3), Ciccolini J(4)(2); EORTC PAMM Group. Author information: (1)SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix ... Congresso a Verona il 06/02/2019 - 09/02/2019 da 16 crediti per Tecnico sanitario laboratorio biomedico, Tecnico sanitario di radiologia medica, Psicologo, Medico chirurgo, Infermiere, Farmacista, Chimico, Biologo: 40th EORTC-PAMM Winter Meeting and Educational Course: preclinical and early-phase clinical pharmacology Anticancer Res. 2019 Jul;39(7):3303-3309. doi: 10.21873/anticanres.13472. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. El Hassouni B(1), Mantini G(1), Li Petri G(1), Capula M(2), Boyd L(1), Weinstein HNW(1), Vallés-Marti A(1), Kouwenhoven MCM(3), Giovannetti E(1 ...
[index]
[7858] [6637] [7899] [8097] [1595] [10244] [3253] [799] [12611] [9056]
#
test2
![[Entertainment] - PAMM namesake Pérez is giving away $50,000 a year. The 2019 prize goes to a U.S. painter](https://external-preview.redd.it/CrpzRW3KA0O3x0qu-k6tfFpnbkcrt3T86JV6aabPw4U.jpg?width=640&crop=smart&auto=webp&s=c855f078de208edb8b500f2a8a2c683ff8cf9db6 "[Entertainment] - PAMM namesake Pérez is giving away $50,000 a year. The 2019 prize goes to a U.S. painter")
